Product information: Active name: LANDIOLOL HYDROCHLORIDE Brand name: RAPIBLYK Innovator name AOP ORPHAN PHARMACEUTICALS AG Approval Date: NOV 22, 2024 Therapeutic activity: LANDIOLOL HYDROCHLORIDE is indicated for the treatment of ultra-short-acting β1-selective blocking agent. It inhibits the positive chronotropic effects of catecholamine adrenaline and norepinephrine on the heart. Route of administration Powder, Intravenous Structure […]
Iodine based contrasting agent: IOMEPROL
IOMEPROL: Active name: IOMEPROL Brand name: IOMERVU Innovator name BRACCO DIAGNOSTICS INC Approval Date: NOV 27, 2024 Therapeutic activity: Tri-iodinated X-Ray contrasting agent. Iomeprol has been investigated for the diagnostic of Coronary Artery Disease. Route of administration Intra arterial/intravenous, Injection Structure Chemical name N,N’-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)- methylamino]-2,4,6-tri-iodo-1,3-benzenedicarboxamide. CAS 78649-41-9 Dosage Available in four iodine concentration. 510 […]
ALK Rearranged lung cancer: Ensartinib
Active name: ENSARTINIB HYDROCHLORIDE Brand name: ENSACOVE Innovator name XCOVERY HOLDINGS INC Approval Date: Dec 18, 2024 Therapeutic activity: ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Route of administration Capsule, oral Structure Chemical name 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-{4-[(3R,5S)- 3,5-dimethylpiperazine-1-carbonyl]phenyl}pyridazine-3-carboxamide, dihydrochloride CAS […]
Treatment of cystic fibrosis: Vanzacaftor
Active name: Vanzacaftor calcium dihydrate Brand name: ALYFTREK Innovator name VERTEX PHARMACEUTICALS INC Approval Date: Dec 20, 2024 Therapeutic activity: Binds to the different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (F508del-CFTR) to increase the amount of CFTR […]
FDA GRANTS ACCELERATED APPROVAL PIRTOBRUTINIB
Active name: Pirtobrutinib Brand name: Jaypirca Innovator name LOXO ONCOLOGY ING Approval Date: Jan 27, 2023 Therapeutic activity: kinase inhibitor used to treat relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy. Route of adminstration Tablet, oral Structure Chemical name 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2S)- 1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide CAS 2101700-15-4 Dosage: […]
Oral ER degrader: Elacestrant
Active name: Elacestrant dihydrochloride Brand name: Orserdu Innovator name STEMLINE THERAPEUTICS INC Approval Date: Jan 27, 2023 Therapeutic activity: Elacestrant is an estrogen receptor antagonist used to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Route of adminstration Tablet, oral Structure […]
A novel drug for activated phosphoinositide-3 kinase delta syndrome: Leniolisib
Active name: Leniolisib Brand name: Joenja Innovator name PHARMING TECHNOLOGIES BV Approval Date: March 24, 2023 Therapeutic activity: phosphoinositide 3-kinase-delta inhibitor that is used to treat activated phosphoinositide 3-kinase delta syndrome Route of adminstration Tablet, oral Structure Chemical name 1-[(3S)-3- [[5,6,7,8-Tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin4-yl]amino]-1-pyrrolidinyl]-1-propanone CAS 1354690-24-6(free base); 1354691-97-6 ( Phosphate salt) Dosage: 70 mg MDD […]
CAPIVASERTIB: Treatment for cancer
Active name: Capivasertib Brand name: Truqap Innovator name ASTRAZENECA PHARMACEUTICAL LTD Approval Date: Nov 16, 2023 Therapeutic activity: Capivasertib, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Route of adminstration Tablet, […]
A Potential sodium-glucose co-transporter 2 (SGLT2) inhibitor: BEXAGLIFLOZIN
Bexagliflozin basic information Active ingredient name: Bexagliflozin Brand name: Brenzavvy, Bexacat (Veterinary) Innovator name THERACOSBIO LLC Approval Date: Jan 20, 2023 Therapeutic activity: Highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly […]
Basic information of 50 new molecular entities approved by the FDA in 2024
Basic information of 50 new molecular entities approved by the FDA in 2024 SNO Trade name Active ingredient Innovator Indication Strength Dosage form 1 Alhemo concizumab-mtci For routine prophylaxis to prevent bleeding episodes in hemophilia A and B 2 Alyfterk vanzacaftor, tezacaftor, and deutivacaftor VERTEX PHARMACEUTICALS INC To treat cystic fibrosis 50 […]